It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal ... Fast Track designation for the treatment of ER+/HER2- metastatic ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

“Onco360 is grateful for the opportunity to partner with the team at Genentech and become a specialty pharmacy provider for Itovebi ™ ,” said Benito Fernandez. “We are proud to add another treatment ...

Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, ...

More people are getting cancer in their 20s, 30s, and 40s, and surviving, thanks to rapid advancement in care. Many will have ...

Source: Getty Images Phase 2 trial results support further development of camizestrant for the treatment of estrogen receptor-positive, HER2-negative breast cancer, according to researchers. The ...

While losing some of her hair during chemotherapy treatment ... progesterone receptor-positive and HER2-positive. After skin cancer, breast cancer is the second most common cancer among women ...

SYNC, its first homegrown CAR-T therapy, one of the first to show promise in treating certain types of brain cancers. This ...

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...